×
Customize
?
Start
Cancer Types
Quick Links
Award Programs
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
Kidney Cancer
Sandy Liu, MD, offers practical advice for patients undergoing treatment for renal cell carcinoma, or kidney cancer, regarding self-education, self-advocacy and adherence to therapy.
Sandy Liu, MD, outlines the available second-line therapeutic options for renal cell carcinoma, or kidney cancer, as well as what factors she considers when selecting from agents in this setting.
Sandy Liu, MD, reflects on the value of targeted agents in the first-line treatment setting of renal cell carcinoma, or kidney cancer, given clinical and personal experience.
Sandy Liu, MD, provides an overview of nonsurgical therapeutic options that have become available to treat renal cell carcinoma, or kidney cancer, in the first-line setting.
Sandy Liu, MD, shares practical advice on using surgery in the first-line setting to treat renal cell carcinoma, or kidney cancer, even regarding advanced-stage disease.
Sandy Liu, MD, discusses the importance of specialized centers, multidisciplinary care and patient input when approaching the treatment of renal cell carcinoma, or kidney cancer.
Sandy Liu, MD, reviews the initial diagnosis and staging of renal cell carcinoma, or kidney cancer, as well as what she discusses with patients who are first presenting with this disease.
Brielle Urciuoli
PD-1 and PD-L1 inhibitors are generally well-tolerated, so most patients face little or no issues with the drugs. However, there are still some things to look out for.
Brielle Urciuoli
Immunotherapy is making landmark change in the treatment of patients with genitourinary (GU) cancers, with bladder cancer being the pioneer in the field, having five FDA-approved checkpoint inhibitors. But kidney cancer is not far behind, with a breakthrough therapy designation granted for a Keytruda (pembrolizumab) combination this past January.
Brielle Urciuoli
The Food and Drug Administration (FDA) approved the immunotherapy combination of Yervoy (ipilimumab) plus Opdivo (nivolumab) to treat patients with intermediate- or poor-risk advanced renal cell carcinoma in the frontline setting.